课题基金 / 基金详情

Therapeutic Editing of Rod Glycolysis Rescues Retinal Degeneration

Therapeutic Editing of Rod Glycolysis Rescues Retinal Degeneration
杆状糖酵解的治疗性编辑可挽救视网膜变性
批准号:
10607717
负责人:
Nicholas David Nolan
金额:
$4.77万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-02-01 至 2026-01-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy, caused by more than 3100 mutations in 80 genes that are primarily specific to rod photoreceptors. Following the major rod death phase, cone death occurs regardless of the underlying gene mutations. However, there exists a knowledge gap in understanding how aerobic glycolysis in cones impacts the delicate “metabolic coupling” between cones and retinal pigment epithelium (RPE) in RP. In this proposal, we hypothesize that reprogramming rod and cone aerobic glycolysis can promote cone survival in RP independent of the underlying rod-specific gene mutations. To test this hypothesis, we propose the following specific aims. In Aim 1, we will determine whether enhanced aerobic glycolysis in cone photoreceptors can promote their survival in a novel genetic mouse model. In Aim 2, we will test the potential of gene therapy to slow photoreceptor degeneration by enhancing aerobic glycolysis in mouse models of RP and characterizing the metabolic changes that occur. Lastly, in Aim 3, we will evaluate the safety profile of the gene therapy described in Aim 2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金